A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvement
ConclusionHAI oxaliplatin combined with capecitabine +/ − bevacizumab was well-tolerated and was associated with favorable outcomes in selected patients.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Anemia | Avastin | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Colorectal Cancer | Drugs & Pharmacology | Eloxatin | Liver | Oral Cancer | Pancreas | Pancreatic Cancer | Thrombocytopenia | Toxicology | Urology & Nephrology | Women | Xeloda